At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
sitagliptin +1 moredrug
Likely dose
sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)
European Foundation for the Study of Diabetes·interventional·Posted Jul 12, 2010·Updated Jul 31, 2018
In Brief
A Phase 2 clinical trial evaluating sitagliptin and Insulin for Type 1 Diabetes. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The aim of this study is to investigate the protective effects of sitagliptin on β cell function in patients with adult-onset latent autoimmune diabetes (LADA) and its mechanisms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesChina
CollaboratorsChinese Medical Association, Eli Lilly and Company
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJul 2010
Primary CompletionJul 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJul 12, 2010
Enrollment StartJan 1, 2010
Primary CompletionJul 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 16.0 years ago
Interventions
sitagliptindrug
sitagliptin tablet,100 mg p.o. qd,2 year
Insulindrug